Overexpression of the RNA-binding proteins Lin28B and IGF2BP3 (IMP3) is associated with chemoresistance and poor disease outcome in ovarian cancer

Evaluation of effects of copper histidine on copper transporter 1-mediated accumulation of platinum and oxaliplatin-induced neurotoxicityin vitroandin vivo

(2013) Virginia Ip et al.   CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY

Mechanisms of Lin28-Mediated miRNA and mRNA Regulation—A Structural and Functional Perspective

(2013) Florian Mayr et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Type-Specific Cell Line Models for Type-Specific Ovarian Cancer Research

(2013) Michael S. Anglesio et al.   PLoS One

Lin28B Is an Oncofetal Circulating Cancer Stem Cell-Like Marker Associated with Recurrence of Hepatocellular Carcinoma

(2013) Shu-Wen Cheng et al.   PLoS One

Evaluating cell lines as tumour models by comparison of genomic profiles

(2013) Silvia Domcke et al.   Nature Communications

Bevacizumab in the Treatment of Ovarian Cancer

(2012) Florian Heitz et al.   ADVANCES IN THERAPY

High expression of Lin28 is associated with tumour aggressiveness and poor prognosis of patients in oesophagus cancer

(2012) R Hamano et al.   BRITISH JOURNAL OF CANCER

Functional study of risk loci of stem cell-associated gene lin-28B and associations with disease survival outcomes in epithelial ovarian cancer

(2012) L. Lu et al.   CARCINOGENESIS

Insulin-like growth factor 2 messenger RNA binding protein 3 (IGF2BP3) is a marker of unfavourable prognosis in colorectal cancer

(2012) Paul Lochhead et al.   EUROPEAN JOURNAL OF CANCER

Investigation of peripubertal expression of Lin28a and Lin28b in C57BL/6 female mice

(2012) Anthony Grieco et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY

LIN28B Promotes Colon Cancer Progression and Metastasis

(2011) C. E. King et al.   CANCER RESEARCH

Stem Cell Pathways Contribute to Clinical Chemoresistance in Ovarian Cancer

(2011) A. D. Steg et al.   CLINICAL CANCER RESEARCH

RNA-binding protein LIN28 is a sensitive marker of ovarian primitive germ cell tumours

(2011) Debin Xue et al.   HISTOPATHOLOGY

Cisplatin treatment of primary and metastatic epithelial ovarian carcinomas generates residual cells with mesenchymal stem cell-like profile

(2011) Ardian Latifi et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

Predictive and prognostic value of human copper transporter 1 (hCtr1) in patients with stage III non-small-cell lung cancer receiving first-line platinum-based doublet chemotherapy

(2011) Helen H.W. Chen et al.   LUNG CANCER

Deregulation of MYCN, LIN28B and LET7 in a Molecular Subtype of Aggressive High-Grade Serous Ovarian Cancers

(2011) Åslaug Helland et al.   PLoS One

Enhancing Tumor-Specific Uptake of the Anticancer Drug Cisplatin with a Copper Chelator

(2010) Seiko Ishida et al.   CANCER CELL

Lin28: A MicroRNA Regulator with a Macro Role

(2010) Srinivas R. Viswanathan et al.   CELL

The use of insulin like-growth factor II messenger RNA binding protein–3 in diagnostic pathology

(2010) Jennifer J. Findeis-Hosey et al.   HUMAN PATHOLOGY

Pluripotency factors Lin28 and Oct4 identify a sub-population of stem cell-like cells in ovarian cancer

(2010) S Peng et al.   ONCOGENE

Identifying LRRC16B as an oncofetal gene with transforming enhancing capability using a combined bioinformatics and experimental approach

(2010) C-C Hsu et al.   ONCOGENE

The Oncofetal Protein IMP3

(2009) Wenxin Zheng et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Diffuse Expression of RNA-Binding Protein IMP3 Predicts High-Stage Lymph Node Metastasis and Poor Prognosis in Colorectal Adenocarcinoma

(2009) Ray-Hwang Yuan et al.   ANNALS OF SURGICAL ONCOLOGY

Pluripotent factor lin-28 and its homologue lin-28b in epithelial ovarian cancer and their associations with disease outcomes and expression of let-7a and IGF-II

(2009) Lingeng Lu et al.   EUROPEAN JOURNAL OF CANCER

Phase II Study of Carboplatin, Paclitaxel, and Bevacizumab With Maintenance Bevacizumab As First-Line Chemotherapy for Advanced Müllerian Tumors

(2009) Richard T. Penson et al.   JOURNAL OF CLINICAL ONCOLOGY

Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial

(2009) Noriyuki Katsumata et al.   LANCET

IGF2BP3 (IMP3) expression is a marker of unfavorable prognosis in ovarian carcinoma of clear cell subtype

(2009) Martin Köbel et al.   MODERN PATHOLOGY

Lin28 promotes transformation and is associated with advanced human malignancies

(2009) Srinivas R Viswanathan et al.   NATURE GENETICS

RNA-binding protein insulin-like growth factor II mRNA-binding protein 3 expression promotes tumor invasion and predicts early recurrence and poor prognosis in hepatocellular carcinoma

(2008) Yung-Ming Jeng et al.   HEPATOLOGY

The Role of Cellular Accumulation in Determining Sensitivity to Platinum-Based Chemotherapy

(2007) Matthew D. Hall et al.   Annual Review of Pharmacology and Toxicology